Arrowhead Pharmaceuticals宣布,其研发中的药物Plozasiran在临床试验中持续展现出稳定的安全性特征,期间未观察到新的安全信号。这一结果进一步支持了该药物的开发前景。
Arrowhead Pharmaceuticals宣布,其研发中的药物Plozasiran在临床试验中持续展现出稳定的安全性特征,期间未观察到新的安全信号。这一结果进一步支持了该药物的开发前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.